Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Rxo (RXO) over the last 5 years, with Q3 2025 value amounting to -$3.0 million.

  • Rxo's Cash from Financing Activities fell 10027.65% to -$3.0 million in Q3 2025 from the same period last year, while for Dec 2025 it was $1.0 million, marking a year-over-year decrease of 9990.97%. This contributed to the annual value of $1.0 million for FY2025, which is 9990.97% down from last year.
  • Rxo's Cash from Financing Activities amounted to -$3.0 million in Q3 2025, which was down 10027.65% from -$3.0 million recorded in Q2 2025.
  • In the past 5 years, Rxo's Cash from Financing Activities ranged from a high of $1.1 billion in Q3 2024 and a low of -$145.0 million during Q4 2022
  • For the 5-year period, Rxo's Cash from Financing Activities averaged around $48.8 million, with its median value being -$3.5 million (2023).
  • In the last 5 years, Rxo's Cash from Financing Activities tumbled by 41785.71% in 2022 and then soared by 2722500.0% in 2024.
  • Quarter analysis of 5 years shows Rxo's Cash from Financing Activities stood at -$28.0 million in 2021, then plummeted by 417.86% to -$145.0 million in 2022, then skyrocketed by 31.03% to -$100.0 million in 2023, then surged by 101.0% to $1.0 million in 2024, then plummeted by 400.0% to -$3.0 million in 2025.
  • Its Cash from Financing Activities was -$3.0 million in Q3 2025, compared to -$3.0 million in Q2 2025 and $7.0 million in Q1 2025.